PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 10, 2020ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)197 citationsOpen Access

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

View Full Paper
DWDavid C. WheelerBSBergur V. StefánssonМБМ. М. Батюшин

Key Points

  • To describe the baseline characteristics of participants enrolled in the DAPA-CKD trial evaluating dapagliflozin in patients with chronic kidney disease.
  • Enrolled participants with chronic kidney disease (CKD Stages 2–4) and elevated albuminuria, with or without type 2 diabetes.
  • Required participants to be receiving background renin-angiotensin system blocking therapy.
  • Enrolled a broad spectrum of participants presenting with varied underlying kidney diseases.
  • Established the baseline cohort to evaluate the efficacy and safety of dapagliflozin in slowing disease progression.

Abstract

Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wheeler et al. (2020) studied this question.

synapsesocial.com/papers/69df12429b582f29b9591711https://doi.org/10.1093/ndt/gfaa234
Ask AI
Helpful
Bookmark
Share
View Full Paper